Home › Chronic Pain › Indiana › Indianapolis
Chronic Pain clinical trials in Indianapolis, IN
5 studies for Chronic Pain are looking for participants at sites in and around Indianapolis (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Options for Pain Management Using Nonpharmacological Strategies
Recruiting
- Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis
Pancreatic Quantitative Sensory Testing (P-QST) to Predict Treatment Response for Pain in Chronic Pancreatitis
Recruiting
- Indiana University Medical Center, Indianapolis
Equipping Patients Using Interventions for Pain and Depression
Recruiting
- Eskenazi Health Primary Care, Indianapolis
Better Options for Chronic Cancer Pain
RecruitingPhase 4Healthy volunteers welcome
- Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis
Stepped-Care Intervention of Music and Imagery to Assess Relief (SCIMITAR) Trial
Recruiting
- Veterans Health Indiana, Indianapolis
About Chronic Pain
Chronic pain lasts longer than three months or the time in which you should have healed. It is not always curable, but treatments can help.
More about Chronic Pain on MedlinePlus
Chronic Pain trials in other cities
- Boston, MA18 studies
- Chicago, IL13 studies
- Baltimore, MD9 studies
- Houston, TX8 studies
- Pittsburgh, PA7 studies
- San Francisco, CA7 studies
- Minneapolis, MN7 studies
- Mountain View, CA7 studies
- New Haven, CT7 studies
- Durham, NC6 studies
- New York City, NY6 studies
- Cincinnati, OH5 studies
Other studies in Indianapolis
- Non-Small Cell Lung Cancer32 studies
- Cancer (all types)24 studies
- Heart Failure24 studies
- Obesity22 studies
- Breast Cancer19 studies
- Ovarian Cancer18 studies
- Metastatic Cancer17 studies
- Colorectal Cancer17 studies
- Cardiovascular Disease16 studies
- Lung Cancer16 studies
- Type 1 Diabetes14 studies
- Overweight14 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.